Global Multi Cancer Early Detection Market sustaining 15–20% CAGR via precision medicine 2030

The multi cancer early detection market is expected to grow at a CAGR of around 15-20% during the forecast period. This growth is primarily due to the rising awareness and increasing demand for early-stage screening tools, especially as cancer rates continue to rise globally, and technological advancements in screening methods. However, high costs and strict regulations can still hinder the market growth.

Multi Cancer Early Detection (MCED) refers to tests designed to detect multiple cancers, often from a single blood sample, unlike traditional methods, which can include multiple diagnostic tests or biopsies. These tests look for signs like DNA methylation patterns or small traces of tumor DNA floating in the bloodstream. The primary goal is early cancer detection, ideally before any symptoms appear, so the overall treatment is more effective and less expensive.

Download a free sample report now 👉
https://meditechinsights.com/multi-cancer-early-detection-market/request-sample/

Global cancer burden and the rising shift toward multi cancer early detection
The primary factor driving this market is the simple fact that cancer is still one of the leading causes of mortality around the world. According to an article published by the WHO, there were around 20 million new cases of cancer and 9.7 million deaths from cancer in the year 2022. The burden is expected to increase by 77% by 2050, and will further put more pressure on healthcare systems. The rising awareness about early detection of cancer and the surge in the number of cancer cases globally have spurred a major shift in screening methods. Instead of waiting for symptoms or relying on invasive, one cancer at a time tests, many healthcare providers are now leaning toward quicker, more inclusive methods like MCED, which requires a single blood draw and can check for multiple cancers, making it not just convenient but also more likely to get people screened in the first place. As clinical evidence continues to build and regulatory pathways evolve, these tests are poised to see much wider adoption in the years ahead.

DNA methylation profiling: a breakthrough enhancing test accuracy and adoption
cfDNA methylation profiling is one of the notable innovations making MCED more accurate and practical. Traditional screening methods include hunting for specific mutations; this test looks at how DNA is tagged with chemical markers called methylation which changes depending on the type and location of cancer. Even if there’s only a tiny amount of tumor DNA in the blood, these unique patterns can still be detected and used to trace the cancer’s origin. The test gives better precision, compared to other methods, meaning fewer false alarms and less need for stressful follow-up tests. The preliminary data for this test seems to be promising, due to which physicians are incorporating it in everyday preventive care, not just for early diagnosis, but for the entire conversation around cancer care. For instance, in February 2025, GRAIL partnered with Quest Diagnostics to make its Galleri test directly accessible to over 500,000 healthcare providers and 7,400 collection sites across the US through Quest Diagnostics' ordering system

Competitive Landscape Analysis
The global multi cancer early detection market is marked by the presence of established and emerging market players such Illumina, Inc.; GRAIL, Inc.; Exact Sciences Corporation; FOUNDATION MEDICINE, INC.; Guardant Health; Freenome Holdings, Inc; Elypta AB; AnchorDx and Burning Rock Biotech Limited among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.

Download a sample report for in-depth competitive insights
https://meditechinsights.com/multi-cancer-early-detection-market/request-sample/

Global Multi Cancer Early Detection Market Segmentation
This report by Medi-Tech Insights provides the size of the global multi cancer early detection market at the regional- and country-level from 2023 to 2030. The report further segments the market based on type and end-user.
Market Size & Forecast (2023-2030), By Type, USD Million
• Liquid Biopsy
• Gene Panel
• LDT & Others
Market Size & Forecast (2023-2030), By End-user, USD Million
• Hospitals
• Diagnostic Centers
• Others
Market Size & Forecast (2023-2030), By Region, USD Million
• North America
o US
o Canada
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o India
o Japan
o Rest of Asia Pacific
• Latin America
• Middle East & Africa
About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.